The DOI matches its Crossref record; 113 of the 114 references it cites were found in a registry or an index.
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Open accessAbstract
A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions, and recommend standard approaches for the workup of cases and their clinico‐pathologic correlation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, there is a long, prodromal stage in AD prior to the irreversibly progressive decline of cognition (Hyman et al., 2012).”
From Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression (2020) · cites this paper as Hyman et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current criteria use an ABC scoring system that requires the presence of amyloid plaques and tau neurofibrillary tangles to describe the amount of AD neuropathological change ranging from none to low to intermediate to high amounts of change.”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both Aβ and paired helical filament (PHF) tau deposits are required to fulfill neuropathologic criteria for AD [105,106]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The new NIA criteria use the same combination of NPs and Braak stage as the minimum lesion density necessary for attributing the cause of dementia to AD (39, 40).”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
From Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia (2022) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
From Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia (2022) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The staging scheme is widely used in neuropathologic criteria for AD [69, 70].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The most current set of criteria for the neuropathological assessment of Alzheimer’s disease termed the 2012 National Institute on Aging-Alzheimer’s Association Guidelines are based on the semi-quantitative measure of Thal Aβ amyloid phase, Braak NFT stage and CERAD neuritic plaque score, and they are applicable to patients with or without dementia [69].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“For cases with incomplete clinical history, higher levels of AD neuropathologic change typically are correlated with greater likelihood of cognitive impairment [29].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The shortcomings of the NIA-Reagan criteria have been recognized and a revised set of criteria are currently in press (39, 40).”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“these findings were consistent with a high degree of AD neuropathology per the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria [3–7].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“By NIA-AA criteria, the findings met criteria for “high level” AD neuropathology [3–7].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Finally, we noticed that the glycolysis pathway genes were maximally expressed at different points in global AD progression for each region (pathology diagnosis by ABC score)29,30.”
From Single-cell multiregion dissection of Alzheimer’s disease (2024) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Neuropathologic diagnosis of AD was in accordance with current NIA-AA guidelines (Hyman et al., 2012; Montine et al., 2012).”
From Cholesterol and matrisome pathways dysregulated in astrocytes and microglia (2022) · cites this paper as Hyman et al., 2012
In the citing paper
“Neuropathological examination included Braak and Braak staging for plaques and tangles and diagnosis of neuropathological AD using National Institute on Aging-Reagan criteria [47].”
From Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain (2020) · cites this paper as [47]
In the citing paper
“Anti-inflammatory DAM and pro-inflammatory DAM module members overlapped (FDR < 10%) with human protein modules (M2, M4, M35, unadjusted p-values < 0.01) that were also positively associated with Braak and CERAD neuropathological grades in human AD (Fig. 9e) [58].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [58]
In the citing paper
“Neuropathology criteria for Alzheimer’s disease provide no cutoff for establishing Alzheimer’s disease diagnosis, but only define low, intermediate, or high levels of Alzheimer’s disease neuropathological change.14”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [14]
In the citing paper
“Neuropathological criteria for the diagnosis of AD were established by the National Institute on Aging–Alzheimer Association (NIA–AA)4 and were updated in 2012 to reflect the current thinking on AD pathological assessment.5,6”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Neuropathological assessment was performed by 2 authors (T.G.B. and T.J.M.) blinded to clinical and imaging results and using NIA–AA diagnostic scoring guidelines.5,40”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Furthermore, although these areas are key in early NFT accumulation in AD, isolated tau in these regions can represent B1-level NFTs, which are associated with not or low levels of ADNC.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Analyses from the National Alzheimer Coordinating Center pathological database have indicated that individuals with a B2 score had clinically normal result at a rate of 25.3% (34 of 134), and 41 (37.6%) of 109 people with Aβ at autopsy had a B2 score.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Results of this study support the hypothesis that, with a high sensitivity and moderate to high specificity, PET imaging with [18F]flortaucipir is able to identify the underlying presence of NFTs at the B3 level and a high level of ADNC per the NIA–AA criteria, consistent with a neuropathological diagnosis of AD.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“zNFT stage should be determined by the method of Braak [19,20].”
InfluentialStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“From the clinical perspective, the concept of AD has evolved to include patients with milder symptoms [2], including the proposition that there is a preclinical phase of the illness [3].”
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Self-citationDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citation
Flagged first, then by citations
1 of the 114 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 1,032
Expression of A152T human tau causes age‐dependent neuronal dysfunction and loss in transgenic mice
Maeda, S., Djukic, B., Taneja, P., Yu, G.-Q., Lo, I., Davis, A., Craft, R., Guo, W., Wang, X., Kim, D., et al. (2016) · EMBO Reports · doi:10.15252/embr.201541438 · Cited by 133
Self-citationCerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
Zhou, X., Sun, L., Bracko, O., Choi, J. W., Jia, Y., Nana, A. L., Brady, O. A., Hernández, J. C. C., Nishimura, N., Seeley, W. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms15277 · Cited by 132
Hampel, H., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., Cavedo, E., Melo dos Santos, A., Epelbaum, S., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.015 · Cited by 129
Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case.
Marquié, M., Verwer, E. E., Meltzer, A. C., Kim, S. J. W., Agüero, C., Gonzalez, J., Makaretz, S. J., Siao Tick Chong, M., Ramanan, P., Amaral, A. C., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0482-0 · Cited by 128
Self-citationNeurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology
Nana, A. L., Sidhu, M., Gaus, S. E., Hwang, J., Li, L., Park, Y., Kim, E. J., Pasquini, L., Allen, I. E., Rankin, K. P., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1942-8 · Cited by 123
What causes neurodegenerative disease?
Armstrong, R. A. (2020) · Folia Neuropathologica · doi:10.5114/fn.2020.96707 · Cited by 143
Roemer, S. F., Grinberg, L. T., Crary, J. F., Seeley, W. W., McKee, A. C., Kovács, G. G., Beach, T. G., Duyckaerts, C. J., Ferrer, I., Gelpí, E., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02479-4 · Cited by 130
Self-citation(2022) · doi:10.1038/s41467-022-34129-4 · Cited by 128
Self-citationImaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
Chiotis, K., Saint‐Aubert, L., Savitcheva, I., Jelić, V., Andersen, P., Jonasson, M., Eriksson, J., Lubberink, M., Almkvist, O., Wall, A. E., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3363-z · Cited by 131
Rangaraju, S., Raza, S. A., Li, N. X., Betarbet, R., Dammer, E. B., Duong, D., Lah, J. J., Seyfried, N. T., & Levey, A. I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00405 · Cited by 126
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Collij, L. E., Bollack, A., Joie, R. L., Shekari, M., Bullich, S., Roé-Vellvé, N., Koglin, N., Jovalekic, A., García, D. V., Drzezga, A. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14336 · Cited by 130
Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies
Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., McCarty-Wood, E., Van Deerlin, V. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.04.025 · Cited by 125
Self-citationEpigenomics of Alzheimer's disease
Bennett, D. A., Yu, L., Yang, J., Srivastava, G. P., Aubin, C., & Jager, P. L. D. (2014) · Translational research · doi:10.1016/j.trsl.2014.05.006 · Cited by 126
VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases
Quinn, J. P., Kandigian, S. E., Trombetta, B. A., Arnold, S. E., & Carlyle, B. C. (2021) · Brain Communications · doi:10.1093/braincomms/fcab261 · Cited by 124
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
Hall, S., Orru, C. D., Serrano, G. E., Galasko, D. R., Hughson, A. G., Groveman, B. R., Adler, C. H., Beach, T. G., Caughey, B. W., & Hansson, O. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01388-7 · Cited by 128
Self-citationNeurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Neuropathology of dementia in a large cohort of patients with Parkinson's disease
Horvath, J. E., Herrmann, F. R., Burkhard, P. R., Bouras, C., & Kövari, E. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.05.010 · Cited by 124
MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease
Wang, G., Huang, Y. M., Wang, L., Zhang, Y., Xu, J., Zhou, Y., Lourenco, G. F., Zhang, B., Wang, Y., Ren, R., et al. (2016) · Scientific Reports · doi:10.1038/srep26697 · Cited by 126
Paasila, P. J., Davies, D., Kril, J. J., Goldsbury, C. S., & Sutherland, G. T. (2019) · Brain Pathology · doi:10.1111/bpa.12717 · Cited by 120
Petersen, C., Nolan, A. L., de Paula França Resende, E., Miller, Z., Ehrenberg, A. J., Gorno-Tempini, M. L., Rosen, H. J., Kramer, J. H., Spina, S., Rabinovici, G. D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02036-6 · Cited by 113
Modular machine learning for Alzheimer's disease classification from retinal vasculature
Tian, J., Smith, G. E., Guo, H. W., Liu, B., Pan, Z., Wang, Z., Xiong, S., & Fang, R. (2021) · Scientific Reports · doi:10.1038/s41598-020-80312-2 · Cited by 131
Recommendations of the Alzheimer's Disease–Related Dementias Conference
Montine, T. J., Koroshetz, W. J., Babcock, D., Dickson, D. W., Galpern, W. R., Glymour, M. M., Greenberg, S. M., Hutton, M. L., Knopman, D. S., Kuzmichev, A. N., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000733 · Cited by 122
Self-citationNobuhara, C. K., DeVos, S. L., Commins, C., Wegmann, S., Moore, B. D., Roe, A. D., Costantino, I., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.01.022 · Cited by 120
Self-citationMultisite assessment of NIA‐AA guidelines for the neuropathologic evaluation of Alzheimer's disease
Montine, T. J., Monsell, S. E., Beach, T. G., Bigio, E. H., Bu, Y., Cairns, N. J., Frosch, M., Henriksen, J., Kofler, J., Kukull, W. A., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.07.492 · Cited by 113
Self-citationMolecular Basis of Alzheimer’s Disease: Focus on Mitochondria
Oliver, D. M. A., & Reddy, P. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190048 · Cited by 120
Mild to moderate Alzheimer dementia with insufficient neuropathological changes
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Blacker, D., Gómez‐Isla, T., Betensky, R. A., Growdon, J. H., Johnson, K. A., Frosch, M. P., Sperling, R. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24125 · Cited by 120
Self-citationGomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125
Self-citationProkop, S., Miller, K. R., Labra, S. R., Pitkin, R. M., Hoxha, K., Narasimhan, S., Changolkar, L., Rosenbloom, A., Lee, V. M.-Y., & Trojanowski, J. Q. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02048-2 · Cited by 119
Self-citationEvidence of amyloid-β cerebral amyloid angiopathy transmission through neurosurgery
Jaunmuktane, Z., Quaegebeur, A., Taipa, R. J. F., Baptista, M. V., Barbosa, R. P., Koriath, C., Sciot, R., Mead, S., & Brandner, S. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1822-2 · Cited by 118
The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
Handen, B. L., Lott, I. T., Christian, B. T., Schupf, N., O’Bryant, S. E., Mapstone, M. E., Fagan, A. M., Lee, J. H., Tudorascu, D., Wang, M., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12065 · Cited by 116
Is synaptic loss a unique hallmark of Alzheimer’s disease?
Scheff, S. W., Neltner, J. H., & Nelson, P. T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.028 · Cited by 118
Self-citationIn vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
Dynamics of Human Mitochondrial Complex I Assembly: Implications for Neurodegenerative Diseases
Giachin, G., Bouverot, R., Acajjaoui, S., Pantalone, S., & Soler‐López, M. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00043 · Cited by 118
Calderón‐Garcidueñas, A. L., & Duyckaerts, C. J. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00023-7 · Cited by 126
Self-citationLongitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages
Pascoal, T. A., Benedet, A. L., Tudorascu, D., Therriault, J., Mathotaarachchi, S. S., Savard, M., Lussier, F. Z., Tissot, C., Chamoun, M., Kang, M. S., et al. (2021) · Brain · doi:10.1093/brain/awab248 · Cited by 122
Advance of sporadic Alzheimer's disease animal models
Zhang, L., Chen, C., Mak, M. S., Lu, J., Wu, Z., Chen, Q., Han, Y., Li, Y., & Pi, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21624 · Cited by 116
Advances in microstructural diffusion neuroimaging for psychiatric disorders
Pasternak, O., Kelly, S., Sydnor, V. J., & Shenton, M. E. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.04.051 · Cited by 116
Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology
Andrés‐Benito, P., Fernández‐Dueñas, V., Carmona, M., Escobar, L. A., Torrejón-Escribano, B., Aso, E., Ciruela, F., & Ferrer, I. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12386 · Cited by 114
FDG-PET patterns associated with underlying pathology in corticobasal syndrome
Pardini, M., Huey, E. D., Spina, S., Kreisl, W. C., Morbelli, S. D., Wassermann, E. M., Nobili, F. M., Ghetti, B. F., & Grafman, J. H. (2019) · Neurology · doi:10.1212/wnl.0000000000007038 · Cited by 119
Monteiro, C., Tóth, B. I., Brunstein, F., Bobbala, A., Datta, S., Ceniceros, R., Bohorquez, S. M. S., Anania, V. G., Wildsmith, K. R., Schauer, S. P., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207663 · Cited by 113
Slevin, M., Matou, S., Zeinolabediny, Y., Corpas, R., Weston, R., Liu, D., Boras, E., Di Napoli, M., Petcu, E., Sarroca, S., et al. (2015) · Scientific Reports · doi:10.1038/srep13281 · Cited by 115
Theofilas, P., Dunlop, S. R., Heinsen, H., & Grinberg, L. T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142682 · Cited by 119
The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias
Abu‐Rumeileh, S., Capellari, S., Maserati, M. S., Polischi, B., Martinelli, P., Caroppo, P., Ladogana, A., & Parchi, P. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0331-1 · Cited by 119
Bieniek, K. F., Blessing, M. M., Heckman, M. G., Diehl, N. N., Serie, A. M., Paolini, M. A., Boeve, B. F., Savica, R., Reichard, R. R., & Dickson, D. W. (2019) · Brain Pathology · doi:10.1111/bpa.12757 · Cited by 126
Self-citationXia, Y., Prokop, S., Gorion, K.-M. M., Kim, J. D., Sorrentino, Z. A., Bell, B. M., Manaois, A. N., Chakrabarty, P., Davies, P., & Giasson, B. I. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00967-w · Cited by 118
Amylin as a potential link between type 2 diabetes and alzheimer disease
Martínez-Valbuena, I., Valenti‐Azcarate, R., Amat, I., Riverol, M., Marcilla, I., de Andrea, C. E., Sánchez-Arias, J. A., Carmona‐Abellán, M., Martí‐Andrés, G., Erro, M. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25570 · Cited by 120
Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK
Ritchie, D. L., Adlard, P., Peden, A., Lowrie, S., Grice, M. L., Burns, K., Jackson, R. J., Yull, H. M., Keogh, M. J., Wei, W., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1703-0 · Cited by 118
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Tan, R. H., Kril, J. J., Fatima, M., McGeachie, A. B., McCann, H., Shepherd, C. E., Forrest, S. L., Affleck, A. J., Kwok, J. B., Hodges, J. R., et al. (2015) · Brain · doi:10.1093/brain/awv220 · Cited by 113
Baldacci, F., Lista, S., Cavedo, E., Bonuccelli, U., & Hampel, H. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304217 · Cited by 113
FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis
Botha, H., Mantyh, W. G., Murray, M. E., Knopman, D. S., Przybelski, S. A., Wiste, H. J., Graff‐Radford, J., Josephs, K. A., Schwarz, C. G., Kremers, W. K., et al. (2018) · Brain · doi:10.1093/brain/awy049 · Cited by 112
Self-citationStaging of Alzheimer’s disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S. G., & Rosa‐Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 123
Ríos, A. S., Oxenford, S., Neudorfer, C., Butenko, K., Li, N., Rajamani, N., Boutet, A., Elias, G. J. B., Germann, J., Loh, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34510-3 · Cited by 115
Verheijen, J., Van den Bossche, T., van der Zee, J., Engelborghs, S., Sanchez-Valle, R., Lladó, A., Graff, C., Thonberg, H., Pastor, P., Ortega-Cubero, S., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1566-9 · Cited by 112
Shah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., Rappaport, S. A., Quinn, J. F., Wieggers, R. L., Scheltens, P., et al. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt224 · Cited by 112
SIRT3 and mitochondrial metabolism in neurodegenerative diseases
Salvatori, I., Valle, C., Ferri, A., & Carrì, M. T. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.04.012 · Cited by 110
Agujetas, V. R., Barbero‐Camps, E., de Dios, C., Podlesniy, P., Abadin, X., Morales, A., Marı́, M., Trullás, R., & Colell, A. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00435-6 · Cited by 113
Bell, W. R., An, Y., Kageyama, Y., English, C., Rudow, G. L., Pletnikova, O., Thambisetty, M., O'Brien, R., Moghekar, A. R., Albert, M. S., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.215 · Cited by 111
Wilcock, D. M., Hurban, J., Helman, A. M., Sudduth, T. L., McCarty, K. L., Beckett, T. L., Ferrell, J. C., Murphy, M. P., Abner, E. L., Schmitt, F. A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.016 · Cited by 110
MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma
Bekris, L. M., Lutz, F., Montine, T. J., Yu, C. E., Tsuang, D., Peskind, E. R., & Leverenz, J. B. (2013) · Biomarkers · doi:10.3109/1354750x.2013.814073 · Cited by 97
Self-citationDNA methylation signature of human hippocampus in Alzheimer’s disease is linked to neurogenesis
Altuna, M., Urdánoz‐Casado, A., de Gordoa, J. S., Zelaya, M. V., Labarga, A., Lepesant, J. M. J., Roldán, M., Blanco‐Luquin, I., Perdones-Montero, Á., Larumbe, R., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0672-7 · Cited by 107
CCL2 is associated with microglia and macrophage recruitment in chronic traumatic encephalopathy
Cherry, J. D., Meng, G., Daley, S. A., Xia, W., Svirsky, S. E., Alvarez, V. E., Nicks, R., Pothast, M. J., Kelley, H. J., Huber, B. R., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02036-4 · Cited by 112
McAleese, K. E., Colloby, S. J., Thomas, A. J., Al‐Sarraj, S., Ansorge, O., Neal, J., Roncaroli, F., Love, S., Francis, P. T., & Attems, J. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12291 · Cited by 110
Pomilio, C., Gorojod, R. M., Riudavets, M., Vinuesa, A., Presa, J., Gregosa, A., Bentivegna, M., Alaimo, A., Alcon, S. P., Sevlever, G., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00161-9 · Cited by 109
Nucleic acid oxidation: an early feature of Alzheimer's disease
Bradley‐Whitman, M. A., Timmons, M. D., Beckett, T. L., Murphy, M. P., Lynn, B. C., & Lovell, M. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12444 · Cited by 112
Dementia and mild cognitive impairment in adults with intellectual disability: Issues of diagnosis
Krinsky‐McHale, S. J., & Silverman, W. P. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1126 · Cited by 116
Hondius, D., Eigenhuis, K. N., Morrema, T. H. J., van der Schors, R. C., van Nierop, P., Bugiani, M., Li, K. W., Hoozemans, J. J. M., Smit, A. B., & Rozemüller, A. J. M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0540-2 · Cited by 111
[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging
Marquié, M., Siao Tick Chong, M., Antón-Fernández, A., Verwer, E. E., Sáez-Calveras, N., Meltzer, A. C., Ramanan, P., Amaral, A. C., Gonzalez, J., Normandin, M. D., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1740-8 · Cited by 109
Self-citationSerrano‐Pozo, A., Qian, J., Monsell, S. E., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000016 · Cited by 106
Self-citationSeibyl, J. P., Catafau, A. M., Barthel, H., Ishii, K., Rowe, C. C., Leverenz, J. B., Ghetti, B. F., Ironside, J. W., Takao, M., Akatsu, H., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161927 · Cited by 108
Chiotis, K., Saint‐Aubert, L., Rodriguez‐Vieitez, E., Leuzy, A., Almkvist, O., Savitcheva, I., Jonasson, M., Lubberink, M., Wall, A., Antoni, G., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.108 · Cited by 112
Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity
Smith, L. M., & Strittmatter, S. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024075 · Cited by 109
Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice
Babcock, A. A., Ilkjær, L., Clausen, B. H., Villadsen, B., Dissing-Olesen, L., Bendixen, A. T. M., Lyck, L., Lambertsen, K. L., & Finsen, B. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.03.006 · Cited by 107
Proposed research criteria for prodromal behavioural variant frontotemporal dementia
Barker, M. S., Gottesman, R. T., Manoochehri, M., Chapman, S., Appleby, B. S., Brushaber, D. E., Devick, K. L., Dickerson, B. C., Domoto‐Reilly, K., Fields, J. A., et al. (2021) · Brain · doi:10.1093/brain/awab365 · Cited by 110
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 113
Wang, Z., Wang, C., Yuan, B., Liu, L., Zhang, H., Zhu, M., Chai, H., Peng, J., Huang, Y. H., Zhou, S., et al. (2025) · Microbiome · doi:10.1186/s40168-024-02001-w · Cited by 125
Jin, S. C., Pástor, P., Cooper, B., Cervantes, S., Benítez, B. A., Razquín, C., Goate, A., Ibero-American Alzheimer Disease Genetics Group Researchers, & Cruchaga, C. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt137 · Cited by 106
mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders
Ryskalin, L., Limanaqi, F., Frati, A., Busceti, C. L., & Fornai, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082226 · Cited by 110
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Filshtein, T. J., Dugger, B. N., Jin, L., Olichney, J., Farias, S. T., Carvajal‐Carmona, L. G., Lott, P. C., Mungas, D., Reed, B., Beckett, L. A., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180992 · Cited by 106
Tomé, S. O., Vandenberghe, R. R., Ospitalieri, S., Schoor, E. V., Tousseyn, T., Otto, M., Arnim, C. A. F. V., & Thal, D. R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00934-5 · Cited by 105
Self-citationInsights Into the Role of CSF1R in the Central Nervous System and Neurological Disorders
Hu, B., Duan, S., Wang, Z., Li, X., Zhou, Y., Zhang, X., Zhang, Y., Xu, H., & Zheng, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.789834 · Cited by 112
Neuropathology and emerging biomarkers in corticobasal syndrome
Koga, S., Josephs, K. A., Aiba, I., Yoshida, M., & Dickson, D. W. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328586 · Cited by 115
Self-citationBrain pathologies in extreme old age
Neltner, J. H., Abner, E. L., Jicha, G. A., Schmitt, F. A., Patel, E., Poon, L. W., Marla, G., Green, R. C., Davey, A., Johnson, M. A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.009 · Cited by 106
Self-citationCerebrovascular pathology in Down syndrome and Alzheimer disease
Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., & Lott, I. T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0499-4 · Cited by 105
Mitochondrial calcium cycling in neuronal function and neurodegeneration
Walters, G. C., & Usachev, Y. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1094356 · Cited by 105
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106
Self-citationSerrano‐Pozo, A., Qian, J., Muzikansky, A., Monsell, S. E., Montine, T. J., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw026 · Cited by 110
Self-citationValidity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology
Mez, J., Alosco, M. L., Daneshvar, D. H., Saltiel, N. A., Baucom, Z., Abdolmohammadi, B., Uretsky, M., Nicks, R., Martin, B. M., Palmisano, J. N., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12338 · Cited by 107
Age‐dependent impairment of glucose tolerance in the 3xTg‐AD mouse model of Alzheimer's disease
Vandal, M., White, P. J., Chevrier, G., Tremblay, C., St‐Amour, I., Planel, E., Marette, A., & Calon, F. (2015) · The FASEB Journal · doi:10.1096/fj.14-268482 · Cited by 107
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Hertz, L., Chen, Y., & Waagepetersen, H. S. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13107 · Cited by 103
Cykowski, M. D., Takei, H., Schulz, P. E., Appel, S. H., & Powell, S. Z.-E. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0171-1 · Cited by 110
The Exceptional Vulnerability of Humans to Alzheimer’s Disease
Walker, L. C., & Jucker, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.04.001 · Cited by 108
Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia
Santos‐Santos, M., Rabinovici, G. D., Iaccarino, L., Ayakta, N., Tammewar, G., Lobach, I. V., Henry, M. L., Hubbard, I., Mandelli, M. L., Spinelli, E. G., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4309 · Cited by 108
Different microvascular alterations underlie microbleeds and microinfarcts
van Veluw, S. J., Scherlek, A. A., Freeze, W. M., ter Telgte, A., van der Kouwe, A. J., Bacskai, B. J., Frosch, M. P., & Greenberg, S. M. (2019) · Annals of Neurology · doi:10.1002/ana.25512 · Cited by 104
Self-citationWong, D. F., Comley, R. A., Kuwabara, H., Rosenberg, P. B., Resnick, S. M., Ostrowitzki, S., Vozzi, C., Boess, F., Oh, E. S., Lyketsos, C. G., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209916 · Cited by 105
Metadata
- Authors
- Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., Nelson, P. T., Schneider, J. A., Thal, D. R., Thies, B., Trojanowski, J. Q., Vinters, H. V., & Montine, T. J.
- Affiliations
- Harvard University (US)
- National Institutes of Health (US)
- Banner Sun Health Research Institute (US)
- Northwestern University (US)
- Washington University in St. Louis (US)
- Alzheimer's Association Chicago IL USA
- Mayo Clinic (US)
- Service de Neuropathologie Raymond Escourolle Hôpital de la Salpêtriére Paris France
- University of California San Diego (US)
- SUNY Downstate Health Sciences University (US)
- University of Kentucky (US)
- Rush University Medical Center (US)
- Universität Ulm (DE)
- Alzheimer's Association (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- Corresponding author
- Montine, Thomas J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-01
- Volume
- 8
- Issue
- 1
- Pages
- 1-13
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3266529
- OpenAlex
- W2143461767
- Cited by
- 3,092
- References
- 114
- Citations by year
- 2026: 214 · 2025: 285 · 2024: 286 · 2023: 233 · 2022: 260 · 2021: 327 · 2020: 247 · 2019: 228 · 2018: 206 · 2017: 190 · 2016: 170 · 2015: 161 · 2014: 118 · 2013: 115 · 2012: 46
- FWCI
- 98.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer's Association
- Arizona Department of Health Services (211002)
- Arizona Alzheimer’s Consortium
- Deutsche Forschungsgemeinschaft (DFG TH‐624‐4‐1)
- Alzheimer Forschung Initiative (AFI #10810)
- Nancy and Buster Alvord Endowment
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Brain, Humans, Societies, Medical, United States, Consensus Development Conferences, NIH as Topic, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
